Association Between Serum Levels of Sestrin-2 and Galectin-3 and Atrial Remodelling in Patients with Atrial Fibrillation

Abstract

Objective: To explore the prognostic significance of Sestrin-2 and Galectin-3 levels in atrial fibrillation complicated by left atrial remodelling, aiming to offer novel insights for prevention, treatment, and follow-up strategies. Study Design: Analytical study. Place and Duration of the Study: Department of Cardiology, Second People's Hospital of Anhui Province, Hefei, China, from January 2021 to December 2023. Methodology: A total of 188 patients with atrial fibrillation were enrolled and divided into two groups based on the presence or absence of atrial remodelling. Serum levels of Sestrin-2 and Galectin-3, along with baseline clinical data, laboratory examinations, and Doppler echocardiography results, were compared between the groups. Results: The atrial remodelling group showed significantly higher levels of age, AST, Sestrin-2, Galectin-3, and left atrial diameter compared to the non-atrial remodelling group (p <0.05). Multivariate logistic regression analysis indicated that both Sestrin-2 and Galectin-3 were independent risk factors associated with atrial remodelling in patients with atrial fibrillation (p <0.05). The combined assessment of Sestrin-2 and Galectin-3 yielded an area under the receiver operating characteristic (ROC) curve of 0.854, facilitating precise identification of the incidence of atrial fibrillation. Conclusion: The study found that serum levels of Sestrin-2 and Galectin-3 were significantly elevated in the atrial remodelling group compared to the non-atrial remodelling group, suggesting their potential clinical utility in predicting atrial remodelling in patients with atrial fibrillation. These findings are significant for the prevention and treatment of this condition.